Milestone Scientific Inc.
Business Overview: Milestone Scientific Inc. (NYSE American: MLSS)
Executive Summary
Milestone Scientific Inc. is a Delaware medical device company, incorporated in 1989, that develops computer-controlled drug-delivery systems built around its proprietary Dynamic Pressure Sensing (DPS) technology, which controls injection flow rate and measures real-time pressure at the needle tip during dental and medical procedures.
Milestone is a small-cap, patent-heavy device maker whose core dental product (CompuDent/STA, marketed as The Wand) is sold in the U.S., Canada, and over 41 other countries, with export sales representing roughly 40% of 2024 total sales. The company has a history of operating losses and depends on continued access to capital, though it holds a large patent portfolio (about 317 U.S. and foreign patents or applications) and real, FDA-cleared, internationally commercialized products.
1. Core Business Model & How They Work
[ DPS Technology Platform ] ➡️ [ Dental: CompuDent/STA/The Wand ] + [ Medical: CompuFlo Epidural System ] ➡️ [ Direct Sales (US) / Distributors (International) ] ➡️ [ Dental Offices & Clinicians ]- Dental (direct, U.S.): STA system handpieces sold via an online e-commerce portal directly to U.S. and Canadian dental offices; revenue recognized on shipment.
- Dental (international): exclusive and non-exclusive distributors across Asia, Africa, South America, and Europe.
- Medical (CompuFlo Epidural): exclusive international distributors (Italy, Switzerland, Greece, Canada, Middle East) plus a small U.S. direct sales team and a distributor partnership (Axial Biologics) for New Jersey, Texas, and Florida.
2. Product Portfolio
| Product | Category | Purpose | Why It Matters |
|---|---|---|---|
| CompuDent / STA / The Wand | Dental | Computer-controlled, disposable-handpiece dental injection system | Company-described market leader in dental injection technology; sold in 40+ countries |
| CompuFlo Epidural System | Medical | FDA-cleared (510(k)) system confirming epidural space placement via real-time pressure feedback | Has a CPT tracking code and Medicare pricing assignments, giving it a reimbursement pathway other epidural tools lack |
| CompuMed | Medical (legacy) | Earlier FDA-cleared system (2001) | Establishes Milestone's long regulatory track record in computer-controlled delivery |
3. Competitive Landscape
| Category | Named Competitors |
|---|---|
| Dental injection | Quicksleeper and SleeperOne (Dental Hi Tec), Dentapen and Anaeject (Septodont), Calajet (Aseptico), Comfort Control Syringe (Dentsply) |
| Epidural placement | EpiFaith and Episure syringes, Epidrum (Exmoor Innovations) |
| Broader substitute | Traditional disposable and reusable syringes |
Milestone positions itself as a technology pioneer — it describes itself as first to market a virtually painless subcutaneous injection system in 1997 — competing against both dedicated device rivals and the much larger universe of conventional syringes.
4. Strategic Strengths & Risks
Strengths
- Large patent estate: roughly 317 U.S. and foreign patents or applications, a significant IP moat for a company of its size.
- Real-time feedback technology: pressure and audible/visual feedback that the company says competitors generally lack, supporting clinical differentiation.
- Reimbursement infrastructure: CompuFlo's CPT code and Medicare pricing assignments lower the adoption barrier versus devices without a clear billing pathway.
- Long clinical track record: decades of published clinical studies supporting both dental and medical product lines.
Risks
- History of losses and capital dependence: the company states its "immediate future viability" depends on raising additional capital; FY2024 operating loss was $6.8 million against cash used in operations of $2.9 million.
- Thin manufacturing base: informal, purchase-order-based supplier arrangements with no price protection; handpieces are made in China, exposing the company to tariff and U.S.-China trade risk.
- Small direct sales footprint: only 17 full-time employees and a one-person U.S. medical sales team, limiting ability to scale commercial reach without partners.
- Leadership transition: the CEO retired at the end of 2024, with a director serving as interim CEO.
- Listing risk: trades on NYSE American, which carries delisting risk for companies below certain market-cap or share-price thresholds.
- Concentrated ownership: principal holders control about 20% of shares.
5. Financial Overview
| Metric | FY2024 | FY2023 | Strategic Context |
|---|---|---|---|
| Operating loss | $(6.8)M | $(7.1)M | Losses narrowing slightly year over year |
| Net cash used in operations | $(2.9)M | $(5.3)M | Meaningful improvement in cash burn |
| Shares outstanding | 78.0M | — | Small-cap share count |
| Non-affiliate market value (6/30/2024) | $58.2M | — | Micro-cap valuation at $0.68/share |
| Employees | 17 full-time | — | Very lean organization |
6. Summary Conclusion
Milestone Scientific has built a genuinely differentiated, patent-protected technology platform in dental and epidural injection delivery, with real FDA clearances, international commercialization across 40+ countries, and a reimbursement pathway for its medical product that few rivals can match. But it remains a micro-cap with a history of operating losses, a lean 17-person organization, and explicit dependence on continued access to capital — meaning the technology moat is real, but the company's ability to fund its way to profitability before capital runs short is the central risk for any assessment of durability.